Condition
Venom Allergy
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 4 (2)
Trial Status
Recruiting2
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07596303Completed
BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)
NCT06876506Not Yet Recruiting
Identification of B Regulatory Cells by Flow Cytometry
NCT06935890Phase 4Recruiting
Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation
NCT07328178Recruiting
Analysis of the Role of IgE Proteoforms in Health and Disease
NCT00684476Phase 4CompletedPrimary
Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings
Showing all 5 trials